TY - JOUR
T1 - Current and future prospects of nuclear medicine in dementia
AU - Ito, Kengo
AU - Inui, Yoshiki
AU - Kizawa, Tsuyoshi
AU - Kimura, Yasuyuki
AU - Kato, Takashi
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017
Y1 - 2017
N2 - In clinical diagnostic imaging of Alzheimer's disease (AD), MRI and nuclear medicine studies such as cerebral blood flow SPECT are positioned as biomarkers expressing pathological conditions. With understanding its usefulness and limitations, it is important to conduct appropriate application and to utilize the correct evaluation of the result in clinical practice. Although FDG-PET and amyloid PET are still not covered for dementia by health insurance, they are extremely useful for differential diagnosis as well as early diagnosis of AD. As image biomarkers, they may have complementary implications. In addition, tau PET under development not only realizes more accurate evaluation of AD but also is expected to be applied in dementia other than AD. In the future, image biomarkers are indispensable for patient selection (early diagnosis) in mild cognitive impairment (MCI) or earlier stages and for judging the therapeutic effect of interventions in cases when early intervention for AD.
AB - In clinical diagnostic imaging of Alzheimer's disease (AD), MRI and nuclear medicine studies such as cerebral blood flow SPECT are positioned as biomarkers expressing pathological conditions. With understanding its usefulness and limitations, it is important to conduct appropriate application and to utilize the correct evaluation of the result in clinical practice. Although FDG-PET and amyloid PET are still not covered for dementia by health insurance, they are extremely useful for differential diagnosis as well as early diagnosis of AD. As image biomarkers, they may have complementary implications. In addition, tau PET under development not only realizes more accurate evaluation of AD but also is expected to be applied in dementia other than AD. In the future, image biomarkers are indispensable for patient selection (early diagnosis) in mild cognitive impairment (MCI) or earlier stages and for judging the therapeutic effect of interventions in cases when early intervention for AD.
UR - http://www.scopus.com/inward/record.url?scp=85030669076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030669076&partnerID=8YFLogxK
U2 - 10.5692/clinicalneurol.cn-001016
DO - 10.5692/clinicalneurol.cn-001016
M3 - Review article
C2 - 28804110
AN - SCOPUS:85030669076
VL - 57
SP - 479
EP - 484
JO - Clinical Neurology
JF - Clinical Neurology
SN - 0009-918X
IS - 9
ER -